ITOS NASDAQ
iTeos Therapeutics, Inc.
1W: -0.4%
1M: +0.1%
3M: +1.3%
1Y: -41.5%
3Y: -57.0%
5Y: -66.2%
$10.15
Last traded 2025-08-29 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$448.7M
52W Range4.8-17.63
Volume11,006,826
Avg Volume1,341,915
Beta1.49
Dividend—
Analyst Ratings
Company Info
CEOMichel Detheux
Employees173
SectorHealthcare
IndustryBiotechnology
IPO Date2020-07-24
Websiteiteostherapeutics.com
321 Arsenal Street
Watertown, MA 02472-5710
US
Watertown, MA 02472-5710
US
339 217 0161
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Call Matthew | D-Return | 135,937 | $7.05 | 2025-08-29 |
| Call Matthew | D-Return | 146,835 | $4.24 | 2025-08-29 |
| Call Matthew | D-Return | 66,170 | $2.95 | 2025-08-29 |
| Call Matthew | U-Tender | 161,898 | $10.05 | 2025-08-29 |
| Detheux Michel | D-Return | 52,700 | $6.16 | 2025-08-29 |